Grant of Options to Directors
Source: RNS
|
For immediate release |
30 September 2022 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to Directors
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, pursuant to the Company's annual grant of options to employees, the Board has issued options over an aggregate of 837,836 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to the PDMRs detailed below.
Peter Butterfield, Chief Executive Officer, has been awarded 182,500 unapproved share options under the Company's 2015 Share Option Plan; and, 344,931 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.
Andrew Franklin, Chief Financial Officer, has been awarded 121,900 unapproved share options under the Company's 2015 Share Option Plan; and, 188,505 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.
The share options awarded under the 2015 Company Share Option Plan have all been granted with an exercise price of 58.2p, being the closing mid-market price on 28th of September 2022, and become exercisable on 28th of September 2025, being the third anniversary of the date of the grant. The awards granted under the 2019 Long Term Incentive Plan have been granted at nil-cost and also become exercisable on 28th of September 2025.
The vesting of these awards is subject to continued employment and the satisfaction of performance conditions based on EPS and TSR targets.
The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:
|
Name |
Share Options granted |
Total no. of options over ordinary shares now held |
|
Peter Butterfield |
527,431 |
3,372,979 |
|
Andrew Franklin |
310,405 |
2,379,597 |
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging managerial responsibilities.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Mr Peter Butterfield |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Executive Officer - PDMR |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Alliance Pharma plc |
|
|
b) |
Legal Entity Identifier |
N/A |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 1.0 pence each
ISIN: GB0031030819 |
|
|
b) |
Nature of the transaction |
Grant of Options |
|
|
c) |
Currency |
GBP |
|
|
d) |
Price(s) and volume(s) |
Exercise Price (p) |
No. of share options |
|
58.2p |
182,500 |
||
|
Nil |
344,931 |
||
|
|
|||
|
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
Grant of 182,500 options to acquire shares of 1p each at £0.582 per share at an aggregate exercise value of £106,215. Grant of 344,931 options to acquire ordinary shares of 1 pence each at nil-cost.
|
|
|
f) |
Date of the transaction |
29 September 2022 |
|
|
g) |
Place of the transaction |
Outside of trading venue |
|
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Mr Andrew Franklin |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Financial Officer - PDMR |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Alliance Pharma plc |
|
|
b) |
Legal Entity Identifier |
N/A |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 1.0 pence each
ISIN: GB0031030819 |
|
|
b) |
Nature of the transaction |
Grant of Options |
|
|
c) |
Currency |
GBP |
|
|
d) |
Price(s) and volume(s) |
Exercise Price (p) |
No. of share options |
|
58.2p |
121,900 |
||
|
Nil |
188,505 |
||
|
|
|||
|
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
Grant of 121,900 options to acquire shares of 1 pence each at £0.582 per share at an aggregate exercise value of £70,945.80. Grant of 188,505 options to acquire ordinary shares of 1 pence each at nil-cost.
|
|
|
f) |
Date of the transaction |
29 September 2022 |
|
|
g) |
Place of the transaction |
Outside of trading venue |
|
For further information:
|
Alliance Pharma plc |
+ 44 (0)1249 466966 |
|
Head of Investor Relations: Cora McCallum |
+ 44 (0)1249 705168 |
|
ir@allianceph.comk |
|
|
www.alliancepharma.co.uk |
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
|
Mark Court / Hannah Ratcliff |
|
|
|
|
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
|
Nominated Adviser: Freddie Barnfield / Duncan Monteith |
|
|
Corporate Broking: James Black |
|
|
Investec Bank plc |
+ 44 (0) 20 7597 5970 |
|
Corporate Finance: Daniel Adams |
|
|
Corporate Broking: Patrick Robb |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
